Efficacy observation of batroxobin for treatment of vascular cognitive impairment

Qi-jin ZHAI,Xuan-ye YUE,Zhen HONG,Ge-lin XU,Xin-feng LIU

DOI: https://doi.org/10.3969/j.issn.1672-5921.2010.02.005

2010-01-01

Abstract:Objective: To investigate the efficacy and safety of batroxobin in the treatment of vascular cognitive impairment (VCI). Methods: Eighty patients with VCI (but did not reached to dementia) caused by ischemic cerebrovascular disease with cognitive impairment were enrolled. They were randomly allocated into a batroxobin group and a control group (n = 40 in each group). The patients in batroxobin group were administered intravenously with batroxobin ( 5 U batroxobin in 250 mL isotonic saline once a day, 4 times a week) at 1, 8, and 12 weeks after admission. All patients were administered aspirin routinely. The mini-mental state examination (MMSE) scale and activities of daily living (ADL) scale were used to assess the cognitive function and ADL; the levels of fibrinogen (FIB) were measured before and after treatment. The safety of the drug was assessed. Results: Circled digit oneThere were no significant difference in MMSE and ADL scores between the batroxobin and control groups before treatment and at 8 weeks after treatment (P>0.05). At 12 weeks, there were significant difference in MMSE and ADL scores compared to those before treatment (P<0.05 ), but there was no significant difference compared to the control group (P>0.05). At 16 weeks, there was significant improvement in MMSE and ADL scores compare to those before treatment and the control group (P<0.05), while there was no obvious change in MMSE and ADL scores at 8, 12, and 16 weeks in the control group compared to those before treatment (P > 0.05). circled digit 2FIB was 3.50 ± 0.59 and 1.95 ± 0.43 g/L before and after treatment at one week in the batroxobin group, at 8 weeks it was 3.22 ± 0.54 and 2.18 ± 0.46 g/L, and at 12 weeks it was 2.75 ± 0.41 and 2.40 ± 0.41g/L. The differences were statistically significant before and after treatment(P < 0.01). FIB was 3.39 ± 0.61, 3.30 ± 0.59, and 3.24 ± 0.56 g/L, respectively at 1, 8, and 12 weeks in the control group. There were no significant differences (P > 0.05). circled digit 3One patient in the batroxobin group and 2 in the control group had recurrent cerebral infarction(P > 0.05). No adverse events occurred, such as drug allergy, and intracranial or digestive hemorrhage in the batroxobin group. Conclusion: Batroxobin is contributive to improve the cognitive function in patients with VCI and improve their ADL. Moreover, its safety is good.